Review Weighs Benefits, Harms of Mammography Screening

Share this content:
Review Weighs Benefits, Harms of Mammography Screening
Review Weighs Benefits, Harms of Mammography Screening

(HealthDay News) -- The benefits and harms of screening mammography have been quantified in a special communication published online Dec. 30 in JAMA Internal Medicine.

H. Gilbert Welch, MD, MPH, and Honor J. Passow, PhD, from the Dartmouth Institute for Health Policy and Clinical Practice in Hanover, N.H., provide a range of estimates for the absolute frequency of breast cancer deaths avoided, false alarms, and overdiagnosis associated with screening mammography. Data were used from nine randomized trials and are specific to the United States.

The researchers found that, among 1,000 U.S. women aged 50 years who underwent annual screening for 10 years, 0.3 to 3.2 will avoid a breast cancer death; 490 to 670 will experience one or more false alarms; and overdiagnosis and needless treatment will affect three to 14.

"We hope that these data are sufficient for some women to make the decision about whether or not to be screened," the authors concluded. "Some may choose to pursue screening, valuing any potential for benefit as warranting the accompanying harms. Others may choose not to pursue screening, valuing the plausible range for the magnitude of the harms as being too great to justify pursuing the relatively small benefit."


  1. Welch HG, Passow HJ. Quantifying the Benefits and Harms of Screening Mammography. JAMA Intern Med. 2013; doi:10.1001/jamainternmed.2013.13635.

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs